S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.00 (+3.10%)
AAPL   145.91 (+2.43%)
MSFT   248.82 (+3.36%)
META   140.28 (+1.20%)
GOOGL   101.61 (+3.01%)
AMZN   121.08 (+4.49%)
TSLA   248.95 (+2.70%)
NVDA   131.70 (+5.26%)
NIO   16.69 (+7.75%)
BABA   84.13 (+4.57%)
AMD   67.81 (+2.57%)
T   16.09 (+1.19%)
MU   53.97 (+4.35%)
CGC   3.13 (+7.56%)
F   12.32 (+7.41%)
GE   67.54 (+6.19%)
DIS   101.46 (+4.46%)
AMC   7.73 (+12.35%)
PYPL   92.82 (+6.47%)
PFE   44.46 (+0.72%)
NFLX   240.88 (+0.77%)
S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.00 (+3.10%)
AAPL   145.91 (+2.43%)
MSFT   248.82 (+3.36%)
META   140.28 (+1.20%)
GOOGL   101.61 (+3.01%)
AMZN   121.08 (+4.49%)
TSLA   248.95 (+2.70%)
NVDA   131.70 (+5.26%)
NIO   16.69 (+7.75%)
BABA   84.13 (+4.57%)
AMD   67.81 (+2.57%)
T   16.09 (+1.19%)
MU   53.97 (+4.35%)
CGC   3.13 (+7.56%)
F   12.32 (+7.41%)
GE   67.54 (+6.19%)
DIS   101.46 (+4.46%)
AMC   7.73 (+12.35%)
PYPL   92.82 (+6.47%)
PFE   44.46 (+0.72%)
NFLX   240.88 (+0.77%)
S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.00 (+3.10%)
AAPL   145.91 (+2.43%)
MSFT   248.82 (+3.36%)
META   140.28 (+1.20%)
GOOGL   101.61 (+3.01%)
AMZN   121.08 (+4.49%)
TSLA   248.95 (+2.70%)
NVDA   131.70 (+5.26%)
NIO   16.69 (+7.75%)
BABA   84.13 (+4.57%)
AMD   67.81 (+2.57%)
T   16.09 (+1.19%)
MU   53.97 (+4.35%)
CGC   3.13 (+7.56%)
F   12.32 (+7.41%)
GE   67.54 (+6.19%)
DIS   101.46 (+4.46%)
AMC   7.73 (+12.35%)
PYPL   92.82 (+6.47%)
PFE   44.46 (+0.72%)
NFLX   240.88 (+0.77%)
S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.00 (+3.10%)
AAPL   145.91 (+2.43%)
MSFT   248.82 (+3.36%)
META   140.28 (+1.20%)
GOOGL   101.61 (+3.01%)
AMZN   121.08 (+4.49%)
TSLA   248.95 (+2.70%)
NVDA   131.70 (+5.26%)
NIO   16.69 (+7.75%)
BABA   84.13 (+4.57%)
AMD   67.81 (+2.57%)
T   16.09 (+1.19%)
MU   53.97 (+4.35%)
CGC   3.13 (+7.56%)
F   12.32 (+7.41%)
GE   67.54 (+6.19%)
DIS   101.46 (+4.46%)
AMC   7.73 (+12.35%)
PYPL   92.82 (+6.47%)
PFE   44.46 (+0.72%)
NFLX   240.88 (+0.77%)
OTCMKTS:MEOBF

Mesoblast - MEOBF Stock Forecast, Price & News

$0.55
0.00 (0.00%)
(As of 10/3/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.55
$0.55
50-Day Range
$0.48
$0.72
52-Week Range
$0.44
$1.33
Volume
30 shs
Average Volume
1,631 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MEOBF stock logo

About Mesoblast (OTCMKTS:MEOBF) Stock

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Receive MEOBF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

MEOBF Stock News Headlines

Mesoblast Teva Starts
Mesoblast Limited (MESO) Q4 2022 Earnings Call Transcript
MindMed Appoints Schond L. Greenway As CFO
Mesoblast reports FQ3 results
Why Mesoblast Stock Is Plunging After Q4 Earnings Report?
Is Mesoblast (ASX:MSB) Using Debt Sensibly?
Mesoblast Corporate Update and Financial Results Webcast
See More Headlines
Receive MEOBF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:MEOBF
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Silviu Itescu FACP (Age 65)
    FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director
    Comp: $998.7k
  • Mr. Peter T. Howard B.Sc. (Age 54)
    L.L.B., BSc, LLB (Hons), Gen. Counsel & Corp. Exec.
  • Mr. Michael Schuster M.B.A. (Age 45)
    MS, BSc, MBA, Head of Pharma Partnering
  • Dr. Eric A. Rose M.D. (Age 71)
    Chief Medical Officer & Exec. Director
    Comp: $88.06k
  • Ms. Geraldine Storton B.Sc.
    M.B.A., Bsc, MMS, MBA, Head of Regulatory Affairs & Quality Management
  • Dr. Fred Grossman D.O.
    FAPA, Advisor
  • Mr. Andrew Chaponnel B.Com.
    Interim Chief Fin. Officer
  • Ms. Dagmar Rosa-Bjorkeson M.B.A. (Age 58)
    M.S., Chief Operating Officer
  • Mr. Roger D. Brown BA
    Head of Spinal Orthopedic Disorders
  • Dr. Paul J. Simmons BSc (Age 63)
    Ph.D., Head of Research & New Product Devel.













MEOBF Stock - Frequently Asked Questions

How have MEOBF shares performed in 2022?

Mesoblast's stock was trading at $0.97 at the beginning of the year. Since then, MEOBF shares have decreased by 43.1% and is now trading at $0.5517.
View the best growth stocks for 2022 here
.

What is Mesoblast's stock symbol?

Mesoblast trades on the OTCMKTS under the ticker symbol "MEOBF."

How do I buy shares of Mesoblast?

Shares of MEOBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mesoblast's stock price today?

One share of MEOBF stock can currently be purchased for approximately $0.55.

How can I contact Mesoblast?

Mesoblast's mailing address is 55 Collins Street, Melbourne, Victoria (VIC). The official website for the company is www.mesoblast.com. The company can be reached via phone at (139) 639-6036.

This page (OTCMKTS:MEOBF) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.